The language standard for preprints is lower than for formal journals. bioRxiv and medRxiv have no language threshold, and readers tolerate a wider range of narrative register. You can write a Twitter-style short abstract, refer to the manuscript as “this preprint,” and close the Discussion with a slightly casual flourish.
But each of these choices will cost you points at the journal desk review stage. When an editor sees a manuscript that is clearly a direct copy-paste from a preprint, the first impression is that the authors did not re-prepare the language for this submission. Once that impression is layered on top of other minor problems, the grounds for rejection are complete. For a deeper look at how editors ultimately reject manuscripts on “language issues,” see Rejected for “Language Issues”? These Five Problems Are the Real Reason.
The following five language adjustments are the ones non-native authors most often overlook when converting a preprint into a journal submission. Each includes a before-and-after comparison.
1. Preprint-Style Self-References Left in the Journal Version Look Unprofessional
During the preprint phase, authors routinely refer to their manuscript as “this preprint,” “the current preprint,” or “this manuscript posted on bioRxiv.” This phrasing is natural in preprint comment threads and Twitter discussions, but in a formal journal submission it immediately signals that the text has not been rewritten.
When an editor reads a phrase like “this preprint,” they realize the authors have not adjusted the language for the target journal. This is not a fatal error, but it compounds other problems.
Typical original (v1 preprint):
This preprint extends our previous work on TAM polarization by providing single-cell resolution of the macrophage-T cell interactions. The data in this preprint are consistent with recent reports from Smith et al. (2025).
Revised (journal submission version):
This study extends our previous work on TAM polarization by providing single-cell resolution of the macrophage-T cell interactions. Our findings are consistent with recent reports from Smith et al. (2025).
Change “this preprint” to “this study” or “the present work,” and change “the data in this preprint” to “our findings” or “our data.” This is the simplest and most frequently overlooked global replacement to make.
Self-check method: Before submitting the journal version, search the full text for “preprint,” “bioRxiv,” and “medRxiv.” Unless these words appear in a citation of someone else’s preprint, replace every instance with neutral phrasing.
2. A 140-Word Twitter-Style Abstract Needs to Become a Structured 250 to 300-Word Abstract for the Journal
Preprint abstracts can be short and punchy, written for social sharing. This style is even welcome in journals that actively support preprints, such as Science Immediate and Cell Reports.
But the large majority of medical and life science journals require a structured abstract (Background / Methods / Results / Conclusion), typically 250 to 350 words. Submitting a 140-word preprint abstract as the journal abstract leaves the reader (starting with the editor) with a clear sense that information is missing.
Typical original (preprint abstract, approximately 140 words):
Tumor-associated macrophages license CD8+ T cell activation through an interferon-γ–STAT1–PD-L1 axis in microsatellite-unstable colorectal cancer. Using single-cell profiling of 28 treatment-naive patients, we identify a macrophage state that predicts response to checkpoint blockade (AUC 0.82) and is pharmacologically tunable in organoid co-cultures.
This passage is information-dense and suitable for preprint readers who want a quick overview. But for a journal editor, it lacks the structured sections for Background (why this problem matters), Methods (study design and statistical approach), Results (specific numerical ranges), and Conclusion (clinical or mechanistic implications).
Revision strategy:
When expanding a preprint abstract into a structured abstract, apply three principles:
- Background: one to two sentences stating the clinical or biological problem, without reviewing the literature
- Methods: two to three sentences covering study design type, sample size, primary outcome, and statistical approach
- Results: three to four sentences with the main findings, each accompanied by a specific value and a statistical measure
- Conclusion: one to two sentences confined to the scope of the study, avoiding overreach
For guidance on calibrating hedging in the conclusion sentence and making conclusions citable, the preprint-stage strategy is discussed in detail in Five Abstract Language Problems in Preprints. The journal version requires one additional layer of caution compared to the preprint version.
3. Citing Your Own Preprint in the Discussion With Informal Language
When the journal version cites an already-published preprint (for example, preliminary results posted as a preprint while the complete version is submitted to a journal), the citation language in the Discussion is often too colloquial.
Typical original:
As we previously showed in our bioRxiv paper, the IFN-γ signal is required. Here we’ve now confirmed this in a larger cohort.
This passage has two problems. First, “our bioRxiv paper” is an informal citation style; in a journal submission, the standard form is (Wang et al., 2025, bioRxiv) or a “(preprint)” label. Second, “we’ve now confirmed” uses a colloquial contraction; formal journal style calls for “we have confirmed” or a restructured sentence.
Revised:
Consistent with the preliminary observation in our earlier work (Wang et al., 2025, bioRxiv), the IFN-γ signal is required. In the present study, we confirm this requirement in a larger, independent cohort of 186 patients.
The revised version both identifies the preprint source correctly and uses the formal register expected in journal publication. Readers and editors can see the relationship between the prior and current work without ambiguity.
4. The Cover Letter Does Not Mention the Preprint or Explain What Is New
Most journals that support preprints (including Nature family, Cell family, PLOS family, and BMJ family journals) require authors to disclose the preprint in the cover letter. Many authors skip this sentence entirely. When an editor discovers the preprint through an internal database, the omission becomes a first-impression negative.
More importantly, even when the preprint is disclosed, authors frequently fail to explain what substantive work the journal version adds relative to the preprint. Without that sentence, the editor may conclude that the submission is an unchanged copy of the preprint.
Typical cover letter paragraph (needs improvement):
This manuscript has been posted as a preprint on bioRxiv.
This sentence completes the “disclosure” but says nothing about what the journal version contributes.
Revised:
A previous version of this work was posted on bioRxiv (doi: 10.1101/2025.xx.xxxxx) to solicit community feedback. Relative to the preprint, the present manuscript extends the cohort from 120 to 186 patients, includes an independent validation dataset (n = 94), and adds the mechanistic experiments in Figures 5 and 6 that were absent from the preprint version. The primary conclusions are sharpened but directionally unchanged.
This paragraph lets the editor understand in thirty seconds: the preprint has already passed community scrutiny (a positive signal), the journal version represents substantially more work than the preprint (another positive signal), and the conclusions point in the same direction (indicating stable data).
5. The Pre-Submission Inquiry Does Not Address Why Journal Publication Still Adds Value When the Preprint Is Already Public
For high-profile journals such as Nature, Cell, and Science, the pre-submission inquiry is an initial editorial filter. If your study has already been posted as a preprint, the editor will search for the preprint (including Twitter discussions and citation counts) before responding to the inquiry.
This is where preprint authors are most easily tripped up. The editor can see that the preprint has already attracted some attention, and will ask: “If this has already been broadly disseminated, what does publication in Nature/Cell/Science add?”
If the pre-submission inquiry does not proactively answer this question, the editor’s default assumption is that the incremental value is limited, and the reply will be “not of sufficient interest.”
Three elements to include explicitly in a pre-submission inquiry:
- Academic increment: what key experiments or analyses the journal version adds relative to the preprint (for example, an independent validation cohort, mechanistic experiments, expanded clinical sample set)
- Field impact: the discussion, citations, and uptake the preprint has already received in the community (if positive, this signals that the research has traction and explains why formal publication still matters)
- Journal fit: why this study is relevant to the target journal’s specific readership. Avoid generic “broad interest” language; instead connect to specific papers from the journal’s recent issues
Example paragraph:
A preliminary version of this work was posted on bioRxiv in March 2025 and has since been viewed over 12,000 times and cited by 8 peer-reviewed papers, indicating active engagement from the cancer immunology community. The manuscript submitted for your consideration significantly extends the preprint by adding an independent validation cohort of 94 patients and the mechanistic experiments in Figures 5 and 6. Given the journal’s recent emphasis on translational immuno-oncology (e.g., Chen et al., Nature 2025; Garcia et al., Nature 2025), we believe the present study would be of interest to your readership.
This paragraph discloses the preprint, explains the incremental contribution, and connects to the journal’s publication interests.
Preprint-to-Journal Submission Checklist
- Self-reference replacement: Have you searched the full text for “preprint,” “bioRxiv,” and “medRxiv” and replaced every instance (except citations of others’ preprints) with neutral phrasing?
- Abstract structure: Has the abstract been expanded from a short, punchy preprint format to a structured abstract of 250 to 350 words?
- Self-citation language: Does the Discussion cite your own preprint using standard academic citation format? Has informal language such as “our bioRxiv paper” or “we’ve now shown” been removed?
- Cover letter disclosure: Have you disclosed the preprint and explained what substantive work the journal version adds relative to it?
- Pre-submission inquiry (if applicable): Have you addressed the question of why journal publication remains worthwhile even though the preprint is already publicly available?
Moving from a preprint to a journal submission is a complete language upgrade process, not a one-time find-and-replace. It connects directly to the language revision work that should happen during v2 and v3 updates. For guidance on pacing language upgrades through version iterations, see Five Common Language and Structure Mistakes When Updating to v2 on bioRxiv/medRxiv.
If you are preparing to submit a preprint currently on bioRxiv or medRxiv to a target journal and are unsure how much language work remains, send the preprint version and the target journal to contact@scholarmemory.com. I will provide a free sample language review of the preprint-to-journal conversion to help you assess what upgrades are still needed before submission.